Last reviewed · How we verify
NCT03905967: TACE
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
Status unknown
Phase 3
Last updated 20 August 2019
What this trial tests
Phase 3 trial testing TACE in Advanced Hepatocellular Carcinoma in 336 participants. Status unknown.
Timeline
16 June 2019
Primary endpoint
15 April 2023
15 April 2023
15 June 2023
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 336 |
| Start date | 16 June 2019 |
| Primary completion | 15 April 2023 |
| Estimated completion | 15 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- TACE
- Lenvatinib (LENVATINIB) — full drug profile →
Conditions studied
- Advanced Hepatocellular Carcinoma — all drugs for Advanced Hepatocellular Carcinoma →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.
Mossenta M, Busato D, Dal Bo M, Toffoli G. · · 2020 · cited 60× · PMID 32585931 · DOI 10.3390/cancers12061668 -
Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC).
Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. · · 2019 · cited 58× · PMID 31370248 · DOI 10.3390/cancers11081085 -
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.
Fan Y, Xue H, Zheng H. · · 2022 · cited 48× · PMID 35388357 · DOI 10.2147/jhc.s358082 -
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H, Ramjeesingh R, Liu D, Tam VC, et al · · 2021 · cited 38× · PMID 32898239 · DOI 10.1093/jnci/djaa119 -
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.
Shi Y, Cui D, Xia L, Shi D, et al · · 2024 · cited 13× · PMID 39653700 · DOI 10.1038/s41392-024-02085-8 -
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Bitar R, Salem R, Finn R, Greten TF, et al · · 2024 · cited 13× · PMID 39560477 · DOI 10.1148/radiol.232875 -
Current Treatment Methods in Hepatocellular Carcinoma.
Krupa K, Fudalej M, Cencelewicz-Lesikow A, Badowska-Kozakiewicz A, et al · · 2024 · cited 12× · PMID 39682245 · DOI 10.3390/cancers16234059 -
Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies.
Zarlashat Y, Mushtaq H, Pham L, Abbas W, et al · · 2024 · cited 12× · PMID 38999940 · DOI 10.3390/ijms25136830
Verify or expand the search:
- PubMed search for NCT03905967
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TACE
Trials testing the same drug.
- NCT07487662 — TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcin · Phase 2 · not yet recruiting
- NCT07417800 — Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinom · NA · not yet recruiting
- NCT07398664 — H101 Plus TACE for r/m HNSCC · Phase 2 · not yet recruiting
- NCT07340502 — TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma · not yet recruiting
- NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Advanced Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT06811116 — Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta · Phase 1, PHASE2 · recruiting
- NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03905967 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 20 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03905967.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing